Bridgefront Capital’s GSK GSK Stock Holding History

Bridgefront Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339K	Buy	+6,458	New	+$342K	0.09%	343
2025 Q4	–	Sell	-9,531	Closed	-$411K	–	627
2025 Q3	$411K	Buy	9,531 +319	+3%	+$12.5K	0.12%	302
2025 Q2	$354K	Sell	9,212 -2,646	-22%	-$101K	0.09%	376
2025 Q1	$459K	Sell	11,858 -4,807	-29%	-$176K	0.13%	277
2024 Q4	$564K	Buy	16,665 +7,037	+73%	+$253K	0.19%	169
2024 Q3	$394K	Buy	+9,628	New	+$394K	0.15%	251
2024 Q1	–	Sell	-6,234	Closed	-$231K	–	450
2023 Q4	$231K	Buy	+6,234	New	+$224K	0.17%	248
2023 Q1	–	Sell	-13,785	Closed	-$484K	–	487
2022 Q4	$484K	Buy	+13,785	New	+$459K	0.34%	106
2021 Q3	–	Sell	-9,928	Closed	-$494K	–	479
2021 Q2	$494K	Buy	+9,928	New	+$477K	0.19%	176

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bridgefront Capital's GSK Position: Q2 2026 in Review

Bridgefront Capital opened a new position in GSK (GSK) in Q2 2026: 6,458 shares worth $339K. The stake represents 0.09% of the portfolio and ranks #343 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in GSK as recently as Q3 2025.

Bridgefront Capital first reported a position in GSK in Q2 2021 and has held it in 9 quarters since. The position peaked at $564K in Q4 2024. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Bridgefront Capital held 6,458 shares of GSK worth $339K as of Q2 2026.
GSK was a new Bridgefront Capital position in Q2 2026.
GSK made up 0.09% of Bridgefront Capital's portfolio in Q2 2026, its #343 holding.
Bridgefront Capital first reported a position in GSK in Q2 2021 and has held it in 9 quarters since.
Bridgefront Capital's GSK position peaked at $564K in Q4 2024.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.